What are GLP-3s? Meet the new generation of weight-loss drugs with three key ingredients

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.